Trial Profile
Effect of apixaban for anti-atherosclerotic response in atrial fibrillation patients
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Stroke; Thromboembolism
- Focus Therapeutic Use
- 07 Dec 2015 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 15 Mar 2014 New trial record